Vantage logo

Esmo 2018 – Recapping a wild weekend

Vast amounts of data were presented at the Esmo meeting over the weekend. Here is a roundup of Vantage’s analysis of the most crucial trials.

Vantage logo

Esmo 2018 – Loxo sees off Roche 

The first look at data from Roche’s tumour-agnostic project entrectinib look good, but not good enough to unseat Loxo and Bayer’s larotrectinib.


Company Events


Vantage Homepage